These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 18639324)

  • 1. PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer.
    Robinson D; Sandblom G; Johansson R; Garmo H; Aus G; Hedlund PO; Varenhorst E;
    Urology; 2008 Oct; 72(4):903-7. PubMed ID: 18639324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failing to achieve a nadir prostate-specific antigen after combined androgen blockade: predictive factors.
    Park SC; Rim JS; Choi HY; Kim CS; Hong SJ; Kim WJ; Lee SE; Song JM; Yoon JH
    Int J Urol; 2009 Aug; 16(8):670-5. PubMed ID: 19602007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W; Nakabayashi M; Regan MM; Oh WK
    Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase.
    Robinson D; Sandblom G; Johansson R; Garmo H; Stattin P; Mommsen S; Varenhorst E;
    J Urol; 2008 Jan; 179(1):117-22; discussion 122-3. PubMed ID: 17997442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.
    D'Amico AV; Chen MH; Cox MC; Dahut W; Figg WD
    Urology; 2005 Sep; 66(3):571-6. PubMed ID: 16140080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
    Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer.
    Semeniuk RC; Venner PM; North S
    Urology; 2006 Sep; 68(3):565-9. PubMed ID: 17010728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of prostate-specific antigen-doubling time on survival of patients with hormone refractory prostate cancer and bone metastasis: analysis on 56 cases of cancer-specific death.
    Tomioka S; Shimbo M; Amiya Y; Nakatsu H; Murakami S; Shimazaki J
    Int J Urol; 2007 Feb; 14(2):123-7. PubMed ID: 17302568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era.
    Oefelein MG; Agarwal PK; Resnick MI
    J Urol; 2004 Apr; 171(4):1525-8. PubMed ID: 15017212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
    Palma D; Tyldesley S; Pickles T;
    Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
    Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A
    J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
    Park YH; Hwang IS; Jeong CW; Kim HH; Lee SE; Kwak C
    J Urol; 2009 Jun; 181(6):2520-4; discussion 2525. PubMed ID: 19371894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
    Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
    Hussain M; Tangen CM; Higano C; Schelhammer PF; Faulkner J; Crawford ED; Wilding G; Akdas A; Small EJ; Donnelly B; MacVicar G; Raghavan D;
    J Clin Oncol; 2006 Aug; 24(24):3984-90. PubMed ID: 16921051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
    Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
    BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years?
    Mouraviev V; Broadwater G; Sun L; Mayes JM; Moul JW; Polascik TJ
    Urology; 2008 Jun; 71(6):1020-3. PubMed ID: 18267331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.
    Daskivich TJ; Regan MM; Oh WK
    Urology; 2007 Sep; 70(3):527-31. PubMed ID: 17905110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.